Yuhan Valuation Multiples

Yuhan Overview

About Yuhan

Yuhan Corp is a pharmaceutical company. The core business of the company is classified as primary and specialty care, dietary supplements, household and animal care, and contract manufacturing of active pharmaceutical ingredients. The company offers one-stop custom synthesis services from research and development to commercial production of active pharmaceutical products (APIs) and intermediates for the following disease treatments: antivirals (HCV and HIV), antibiotics, antihistamines, antidiabetics, beta-lactamase inhibitors, CNS intermediates, and PEGylated compounds for international markets.

Founded

1926

HQ

Employees

2.1K

Website

yuhan.co.kr

Sectors

BiopharmaceuticalsBioTech

Financials (LTM)

Revenue: $2B

EBITDA: $130M

EV

$5B

Valuation Multiples

Multiples.vc

Start free trial

Yuhan Financials

Yuhan reported last 12-month revenue of $2B and EBITDA of $130M.

In the same LTM period, Yuhan generated $497M in gross profit, $130M in EBITDA, and $126M in net income.

Yuhan P&L

In the most recent fiscal year, Yuhan reported revenue of $1B and EBITDA of $204M.

Yuhan expects next 12-month revenue of XXX and NTM EBITDA of XXX

Yuhan Stock Performance

Yuhan has current market cap of $5B, and enterprise value of $5B.

Yuhan's stock price is $72.89.

Yuhan Valuation Multiples

Yuhan trades at 3.6x EV/Revenue multiple, and 41.8x EV/EBITDA.

Yuhan Financial Valuation Multiples

As of March 28, 2026, Yuhan has market cap of $5B and EV of $5B.

Equity research analysts estimate Yuhan's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX

Yuhan has a P/E ratio of 43.2x.

Yuhan Margins & Growth Rates

Yuhan's revenue in the last 12 month grew by 6%.

Yuhan's revenue per employee in the last FY averaged $0.7M.

Yuhan's rule of 40 is 15% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).

Yuhan's rule of X is 24% (created by Bessemer, rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).

Yuhan Public Comps

See public comps and valuation multiples for other Biopharmaceuticals comps.

Yuhan M&A Activity

Yuhan acquired XXX companies to date.

Last acquisition by Yuhan was on XXXXXXXX, XXXXX. Yuhan acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).

Yuhan Investment Activity

Yuhan invested in XXX companies to date.

Yuhan made its latest investment on XXXXXXXX, XXXXX. Yuhan invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).